Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMC Efficacy Study in Burkina Faso
NCT05478954Phase 4Unknown
- Sponsor
- Malaria Consortium
- Start
- Jul 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sulfadoxine + pyrimethamine and amodiaquine in malaria, sponsored by Malaria Consortium. Primary endpoints: Chemoprevention failure defined by qPCR or microscopy at 1 month and Prevalence of antimalarial resistance markers among chemoprevention failures at 1 month. Status: unknown.
02
Drugs
sulfadoxine + pyrimethamineamodiaquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05478954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478954.